SARS-CoV-2 occurrences caused ovarian, uterine, and vaginal infections due to widespread expression of angiotensin-converting enzyme 2 (ACE2), disrupting the female reproductive system's operations, resulting in infertility and various menstrual illnesses, according to research published in the Journal of Education and Health Promotion in June 2022. As a result, COVID-19 patients were recommended to continue their reproductive examinations once they had recovered. These causes have increased the demand for diagnostic tests. They are likely to compensate for the losses sustained during the first pandemic days, hence fueling the growth of the U.S. women's health diagnostics market over the forecast period.
Access Full Report at https://databridgemarketresearch.com/reports/us-womens-health-diagnostics-market
Data Bridge Market Research analyses that the U.S. Women’s Health Diagnostics Market which was USD 5,962.00 million in 2023, would rocket up to USD 11,462.00 million by 2030, and is expected to undergo a CAGR of 8.5% during the forecast period of 2023-2030. The global market is expected to witness significant growth due to the rising introduction of advanced treatment options and growing population of women at workplaces. Technological advancements and increasing awareness campaigns are also contributing factors.
Growing prevalence of stress in women is expected to drive the market's growth rate
The rising stress level among women is increasing the burden of different illnesses such as obesity, the danger of drug usage, and increased alcohol consumption, all of which contribute to infertility. For example, data updated by the Census Bureau in April 2022 revealed that fertility rates among women aged 20-24 had fallen by 43% in recent years, with only 66.59 births per 1,000 women in that age range, showing a 42.79% reduction in fertility from previous decades. As the rate of infertility among women rises, so will demand for fertility testing and diagnosis in emerging nations, which is expected to drive market expansion throughout the forecast period.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015- 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Diagnostic Devices (Imaging and Monitoring Systems, Biopsy Devices, Reagents and Kits, Biomarkers and Others), Application (Osteoporosis Testing, OVC Testing, Cervical Cancer Testing, Breast Cancer Testing, Pregnancy and Fertility Testing, Prenatal Genetic Screening and Carrier Testing, Infectious Disease Testing, STD Testing and Ultrasound Tests), End User (Hospitals, Diagnostic and Imaging Centres, Clinics and Home Care Setting)
|
|
Market Players Covered
|
bioMérieux SA (France), Carestream Health (U.S.), MEDGYN PRODUCTS, INC. (U.S.), COOK (U.S.), Cardinal Health (U.S.), PerkinElmer Inc. (U.S.), GENERAL ELECTRIC (U.S.), Quest Diagnostics Incorporated (U.S.), Sysmex Corporation (Japan), Siemens (Germany), Hologic Inc. (U.S.), Abbott (U.S.), BD (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Koninklijke Philips N.V. (Netherlands), NeuroLogica Corp. (U.S.), Danaher (U.S.), FUJIFILM Holdings Corporation (Japan), Hitachi, Ltd. (Japan), Canon Inc. (Japan)
|
|
Data Points Covered in the Report
|
In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework
|
Segment Analysis:
The U.S. women's health diagnostics market is segmented based on diagnostic devices, applications, and end users.
- On the basis of by diagnostic devices, the market is segmented into market is segmented into imaging and monitoring systems, biopsy devices, reagents and kits, biomarkers, and others.
Imaging and monitoring systems segment is expected to dominate the U.S. women's health diagnostics market
Among these segments, imaging and monitoring systems dominate the market. This is because imaging technologies such as mammography, ultrasound, and MRI play a crucial role in the early detection and diagnosis of various women's health conditions, including breast cancer.
- On the basis of by application, the market is segmented into market is further segmented into osteoporosis testing, OVC testing, cervical cancer testing, breast cancer testing, pregnancy and fertility testing, prenatal genetic screening and carrier testing, infectious disease testing, STD testing, and ultrasound tests.
Breast cancer testing segment is expected to dominate the U.S. women's health diagnostics market
Among these applications, breast cancer testing is the dominant segment. Breast cancer is one of the most prevalent cancers in women, and early detection through screening tests like mammography is essential for improved treatment outcomes.
- On the basis of end users, the market is segment into market is segmented into hospitals, diagnostic and imaging centres, clinics, and home care settings. Hospitals are the dominant end user in the U.S. women's health diagnostics market. Hospitals typically have advanced diagnostic facilities, multidisciplinary healthcare teams, and access to a wide range of specialized tests, making them the primary choice for women seeking diagnostic services.
Major Players
Data Bridge Market Research recognizes the following companies as the major market players: Cardinal Health (U.S.), PerkinElmer Inc. (U.S.), GENERAL ELECTRIC (U.S.), Quest Diagnostics Incorporated (U.S.), Sysmex Corporation (Japan), Siemens (Germany), Hologic Inc. (U.S.), Abbott (U.S.), BD (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Koninklijke Philips N.V. (Netherlands), NeuroLogica Corp. (U.S.), Danaher (U.S.), FUJIFILM Holdings Corporation (Japan), Hitachi, Ltd. (Japan), Canon Inc. (Japan).
Market Development
- In 2023, Genetic Technologies Limited, a leading global player in genomics-based tests in health, wellness, and serious disease, launched a world-first comprehensive risk assessment test for breast and ovarian cancer. The test, which is designed to evaluate a woman's risk of developing either hereditary or sporadic cancer, involves a simple saliva sample and provides a comprehensive risk assessment by combining other clinical risk factors. The test is a significant advancement in the early detection and personalized treatment of breast and ovarian cancer. It is the first test to offer a comprehensive assessment of a woman's risk of developing both cancers, and it is the only test that combines saliva with other clinical risk factors.
- In 2022, Mylab Discovery Solutions, a prominent Indian diagnostics company, entered the women's healthcare segment with the launch of its home pregnancy test kit, PregaScreen. The test is designed to be easy to use and affordable, and it is available without a prescription. PregaScreen is a qualitative test that detects the presence of human chorionic gonadotropin (hCG) in the urine. hCG is a hormone that is produced by the placenta during pregnancy. If hCG is present in the urine, the test will show a positive result. Mylab plans to expand its product line in the women's healthcare market by introducing a range of innovative and affordable solutions. The company's CEO has emphasized the importance of developing products that are easy to use, accurate, and accessible to women from different parts of the world.
For more detailed information about the U.S. women's health diagnostics market report, click here – https://www.databridgemarketresearch.com/ar/reports/us-womens-health-diagnostics-market
